Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSNNASDAQ:COCPOTCMKTS:HBPCFNASDAQ:MREONASDAQ:REPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsCOCPCocrystal Pharma$1.54+2.0%$1.54$1.12▼$3.26N/A2.0726,647 shs14,097 shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$31.81M-0.221 shsN/AMREOMereo BioPharma Group$2.88+0.2%$2.54$1.58▼$5.02$457.13M0.461.09 million shs799,203 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%COCPCocrystal Pharma+2.05%-0.65%-8.33%+8.45%-33.62%HBPCFHelix Biopharma0.00%0.00%0.00%+31.90%+335.73%MREOMereo BioPharma Group+0.17%+2.68%+8.49%+44.47%-19.92%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma3.2531 of 5 stars3.55.00.00.03.31.70.0HBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AMREOMereo BioPharma Group1.9782 of 5 stars3.63.00.00.00.61.70.0REPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunon 0.00N/AN/AN/ACOCPCocrystal Pharma 3.00Buy$6.00289.61% UpsideHBPCFHelix Biopharma 0.00N/AN/AN/AMREOMereo BioPharma Group 3.20Buy$7.60164.35% UpsideREPHRecro Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HBPCF, MREO, CLSN, REPH, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00COCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/AHBPCFHelix BiopharmaN/AN/AN/AN/A($0.02) per shareN/AMREOMereo BioPharma Group$10M45.71N/AN/A$0.39 per share7.37REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ACOCPCocrystal Pharma-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)HBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%N/AMREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)REPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest HBPCF, MREO, CLSN, REPH, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/A5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52COCPCocrystal PharmaN/A4.574.57HBPCFHelix BiopharmaN/A0.420.99MREOMereo BioPharma GroupN/A8.928.92REPHRecro Pharma2.273.242.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%COCPCocrystal Pharma6.72%HBPCFHelix BiopharmaN/AMREOMereo BioPharma Group62.83%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%COCPCocrystal Pharma28.14%HBPCFHelix Biopharma7.60%MREOMereo BioPharma Group5.50%REPHRecro Pharma14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableCOCPCocrystal Pharma10N/AN/ANot OptionableHBPCFHelix Biopharma953.02 million48.99 millionNot OptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableREPHRecro Pharma18556.42 million48.41 millionOptionableHBPCF, MREO, CLSN, REPH, and COCP HeadlinesRecent News About These CompaniesPharma’s climate change vulnerability and opportunityJuly 19, 2024 | pharmaphorum.comPDorf Ketal's Indian unit acquires veterinary pharma brandApril 10, 2024 | vccircle.comVFuji Pharma Co. Ltd.January 30, 2024 | wsj.comAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croreNovember 22, 2023 | moneycontrol.comRetaining the human element of AI within pharma and healthcareNovember 21, 2023 | pharmaphorum.comPHere's what Wall Street expects from Recro Pharma's earnings reportNovember 7, 2023 | markets.businessinsider.comUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 16, 2023 | theguardian.comMankind Pharma share priceAugust 9, 2023 | livemint.comWhat Wall Street expects from Recro Pharma's earningsAugust 9, 2023 | markets.businessinsider.comMankind Pharma Ltd (MNKI)August 3, 2023 | investing.comEversana and Amazon plan generative AI push in pharmaJuly 30, 2023 | pharmaphorum.comPAurobindo Pharma Ltd.July 24, 2023 | ndtv.comNBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 30, 2023 | bizjournals.comPharma reform: Patients can’t afford to wait. Act now.June 13, 2023 | politico.euPSun Pharma reports "information security incident"; isolates impacted IT assetsMarch 9, 2023 | health.economictimes.indiatimes.comWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLMarch 1, 2023 | ijr.comIAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendFebruary 17, 2023 | moneycontrol.comPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusDecember 20, 2022 | financialexpress.comFPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLJune 24, 2022 | benzinga.comSocietal CDMO IncApril 20, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHBPCF, MREO, CLSN, REPH, and COCP Company DescriptionsImunon NASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Cocrystal Pharma NASDAQ:COCP$1.54 +0.03 (+1.99%) As of 07/3/2025 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 07/3/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Mereo BioPharma Group NASDAQ:MREO$2.88 +0.01 (+0.17%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Recro Pharma NASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
